汉森制药
(002412)
| 流通市值：28.83亿 | | | 总市值：29.14亿 |
| 流通股本：4.98亿 | | | 总股本：5.03亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 88,289,086.59 | 128,022,889.88 | 61,896,678.44 | 109,909,913.2 |
| 应收票据及应收账款 | 388,948,048.67 | 338,263,273.08 | 331,271,261.58 | 356,776,565.62 |
| 其中：应收票据 | 49,783,220.35 | 51,078,920.41 | 36,201,367.88 | 35,782,436.58 |
| 应收账款 | 339,164,828.32 | 287,184,352.67 | 295,069,893.7 | 320,994,129.04 |
| 应收款项融资 | 81,712,662.07 | 86,769,940.56 | 37,716,485.67 | 35,711,276.42 |
| 预付款项 | 4,801,503.36 | 4,361,861.21 | 3,655,699.76 | 4,709,543.52 |
| 其他应收款合计 | 17,279,615.83 | 17,885,668.85 | 6,613,233.62 | 6,978,073.9 |
| 存货 | 212,211,507.99 | 222,876,023.84 | 221,548,287.8 | 221,102,091.51 |
| 其他流动资产 | 76,139,117.21 | 80,872,548.44 | 68,494,000.73 | 67,316,482.12 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,199,045,999.11 | 1,123,168,939.47 | 1,040,122,716.05 | 1,018,103,374.23 |
| 非流动资产: | | | | |
| 长期股权投资 | 787,701,027.88 | 855,753,806.92 | 838,583,389.6 | 852,908,259.3 |
| 投资性房地产 | 3,296,863.15 | 3,361,035.97 | 3,425,208.79 | 3,489,381.61 |
| 固定资产 | 459,539,834.87 | 468,604,464.13 | 472,274,965.5 | 480,129,509.35 |
| 在建工程 | 11,712,845.51 | 10,804,783.15 | 12,584,582.16 | 12,435,091.12 |
| 生产性生物资产 | 9,217,488.86 | 9,748,819.6 | 9,313,672.64 | 9,154,876.63 |
| 无形资产 | 28,925,779.07 | 29,304,538.64 | 29,491,786.16 | 29,914,475.85 |
| 商誉 | 14,789,430.33 | 14,789,430.33 | 14,789,430.33 | 14,789,430.33 |
| 长期待摊费用 | 14,497,216.83 | 14,408,219.51 | 14,587,890.53 | 14,767,561.55 |
| 递延所得税资产 | 2,317,502.9 | 2,422,384.62 | 2,474,912.05 | 2,552,981.3 |
| 其他非流动资产 | 15,069,624.28 | 14,867,824.98 | 15,036,555.79 | 14,985,795.79 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,347,067,613.68 | 1,424,065,307.85 | 1,412,562,393.55 | 1,435,127,362.83 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 2,546,113,612.79 | 2,547,234,247.32 | 2,452,685,109.6 | 2,453,230,737.06 |
| 流动负债: | | | | |
| 短期借款 | 83,134,868.29 | 84,509,144.27 | 79,795,291.53 | 90,514,320.23 |
| 应付票据及应付账款 | 29,542,028.82 | 41,615,472.36 | 23,342,888.21 | 30,027,207.74 |
| 应付账款 | 29,542,028.82 | 41,615,472.36 | 23,342,888.21 | 30,027,207.74 |
| 合同负债 | 1,547,494.21 | 2,722,919.2 | 791,335.25 | 844,550.69 |
| 应付职工薪酬 | 17,959,926.79 | 39,741,974.2 | 17,590,643.65 | 17,735,501.32 |
| 应交税费 | 7,998,566.18 | 10,116,082.39 | 6,264,413.1 | 9,336,914.02 |
| 其他应付款合计 | 155,084,717.57 | 127,054,669.22 | 182,019,217.78 | 197,020,786.87 |
| 其他流动负债 | 32,364,994.62 | 12,556,113.1 | 15,658,462.25 | 8,991,977.75 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 327,632,596.48 | 318,316,374.74 | 325,462,251.77 | 354,471,258.62 |
| 非流动负债: | | | | |
| 递延收益 | 24,096,610.12 | 24,537,295.54 | 24,967,492.96 | 20,163,688.6 |
| 递延所得税负债 | 1,082,465.52 | 998,516.89 | 983,186.55 | 1,004,771.46 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 25,179,075.64 | 25,535,812.43 | 25,950,679.51 | 21,168,460.06 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 352,811,672.12 | 343,852,187.17 | 351,412,931.28 | 375,639,718.68 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 503,200,000 | 503,200,000 | 503,200,000 | 503,200,000 |
| 资本公积 | 234,116,276.27 | 234,116,276.27 | 234,116,276.27 | 234,116,276.27 |
| 其他综合收益 | 9,114,164.36 | 30,451,448.19 | 17,832,929.49 | 24,410,817.17 |
| 盈余公积 | 191,075,411.87 | 191,075,411.87 | 175,822,549.32 | 175,822,549.32 |
| 未分配利润 | 1,255,796,088.17 | 1,244,538,923.82 | 1,170,300,423.24 | 1,140,041,375.62 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 2,193,301,940.67 | 2,203,382,060.15 | 2,101,272,178.32 | 2,077,591,018.38 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 2,193,301,940.67 | 2,203,382,060.15 | 2,101,272,178.32 | 2,077,591,018.38 |
| 负债和股东权益合计 | 2,546,113,612.79 | 2,547,234,247.32 | 2,452,685,109.6 | 2,453,230,737.06 |
| 公告日期 | 2025-04-26 | 2025-04-26 | 2024-10-29 | 2024-08-14 |
| 审计意见(境内) | | 标准无保留意见 | | |